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Intravitreal ranibizumab as adjuvant
treatment for neovascular glaucoma
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ABSTRACT
The purpose of this study was to describe a prospective case series of 5 eyes treated with intravitreal ranibizumab injection for neovascular
glaucoma (NVG). Five patients with clinically uncontrolled NVG secondary to proliferative diabetic retinopathy (4 patients) and
central retinal vein occlusion (1 patient), non-responsive to maximal tolerable medication and panretinal photocoagulation, received
intravitreal ranibizumab injection (0.5 mg). Patients were seen at 1st, 3rd and 7th day after the ranibizumab injection and when it was
necessary. Success was defined as intraocular pressure (IOP) <d” 21mmHg, with or without medication. Those with persistent IOP >
21, despite maximal tolerable medication, underwent trabeculectomy with 0.5mg/ml mitomycin C (MMC) for 1 minute. Failure was
defined as IOP > 21 mmHg, phthisis bulbi, loss of light perception or additional glaucoma surgery. The primary outcome was 6-month
IOP control. Mean IOP before the ranibizumab injection was 37 mmHg (7 mmHg SD). Two out of five eyes underwent only ranibizumab
injection, having an IOP control after the procedure. Three patients were submitted to trabeculectomy with MMC on the 7th day after
the injection. At 6-month follow-up, the mean IOP was 12mmHg (3 mmHg SD). All eyes showed regression of rubeosis iridis and IOP
control. Visual acuity improved in 2 eyes worsened in 1 eye, and remained stable in 2 eyes. These data suggest that intravitreal ranibizumab
injection may be a useful tool in the treatment of NVG.
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RESUMO
O objetivo deste estudo foi descrever uma série de casos prospectivos de 5 olhos tratados com ranibizumabe intravítreo para
glaucoma neovascular (GNV). Cinco pacientes com GNV refratário, secundário a retinopatia diabética proliferativa (4 pacientes)
e oclusão de veia central da retina (1 paciente), não responsivos a terapia medicamentosa máxima tolerada e panfotocoagulação da
retina, receberam ranibizumabe intravítreo (0,5 mg). Os pacientes foram vistos no 1º, 3º e 7º dia após a aplicação e conforme
necessário. O sucesso foi definido como pressão intraocular (PIO) d”21 mmHg, com ou sem uso de medicação antiglaucomatosa.
Aqueles com PIO > 21 mmHg, apesar da medicação máxima tolerada, foram submetidos à trabeculectomia com mitomicina C
(MMC) 0,5mg/mL por 1 minuto. Falência foi definida como PIO > 21 mmHg, phthisis bulbi, perda da percepção de luz ou necessidade
de cirurgia antiglaucomatosa adicional. O resultado primário avaliado foi o controle da PIO após 6 meses do procedimento. A PIO
média antes da injeção era de 37 mmHg (DP=7 mmHg). Dois pacientes foram submetidos somente a injeção intravítrea de
ranibizumabe, obtendo controle da PIO após o procedimento. Três pacientes foram submetidos à trabeculectomia com MMC no 7º
dia após a injeção. Após 6 meses de seguimento, a PIO média era de 12 mmHg (DP=3 mmHg). Todos os olhos mostraram regressão
da rubeosis iriana e controle da PIO. A acuidade visual melhorou em 2 olhos, piorou em 1 olho e permaneceu estável em 2 olhos.
Estas informações sugerem que a injeção intravítrea de ranibizumabe pode ser uma ferramenta útil no tratamento do GNV.
Descritores: Glaucoma neovascular/quimioterapia; Quimioterapia adjuvante; Pressão intraocular;  Injeções intravítreas;
Anticorpos monoclonais/uso terapêutico; Relatos de casos
1.Department of Ophthalmology, Universidade Estadual de Campinas (UNICAMP) – Campinas (SP), Brasil.
Study carried out at department of Ophthalmology, Universidade Estadual de Campinas (UNICAMP) – Campinas (SP), Brasil.
The authors declare no conflicts of interest
RELATO DE CASO
Recebido para publicação em: 5/10/2011 - Aceito para publicação em: 12/1/2012
Rev Bras Oftalmol. 2013; 72 (2): 119-21
120
INTRODUCTION
N eovascular glaucoma (NVG) is a severe form ofglaucoma characterized by rubeosis iridis andintraocular pressure (IOP) elevation. Hypoxic disease
of the retina such as diabetic retinopathy and occlusion of major
retinal vessels account for more than one half of this glaucoma.
Once retinal hypoxia is established the natural history of
neovascular glaucoma can be divided in four stages: prerubeosis
stage, preglaucoma stage, open-angle glaucoma stage, and angle-
closure glaucoma stage.(1)
Panretinal photocoagulation has been shown to
significantly reduce or eliminate anterior neovascularization and
may reverse IOP elevation in the open-angle glaucoma stage.
When the IOP begins to rise, medical therapy is required to
control the pressure during the open-angle glaucoma stage. The
mainstays of the therapy at this stage are drugs that reduce
aqueous production such as carbonic anhydrase inhibitors, topical
beta-blockers and alpha agonists. Although surgical intervention
is often necessary, trabeculectomy alone and other shunt-tube
drainage procedures for NVG are challenging because new
vessels tend to recur, bleed easily, are always associated with
postoperative inflammation and have higher rate of failure to
control IOP.(2) Recent case series have demonstrated a role for
bevacizumab in reducing rubeosis iridis and as an adjunct
treatment for NVG.(2-4)
Intravitreal ranibizumab is the standard of care for the
treatment of exudative macular degeneration. This
pharmacologic agent, which selectively inhibits vascular
endothelial growth factor (VEGF), might be an important
adjunctive therapy in the management of NVG by causing rapid
and consistent regression of neovascularization in the anterior
segment.
The purpose of this study is to describe a prospective case
series of five eyes treated with intravitreal ranibizumab injection
for NVG.
Cases report
A total of 5 patients with clinically uncontrolled NVG,
secondary to proliferative diabetic retinopathy (PDR) (4
patients) and central retinal vein occlusion (CRVO) (1 patient),
non-responsive to maximal tolerable medication  and panretinal
photocoagulation,  received intravitreal ranibizumab (0.5 mg)
injection via the pars plana and if necessary were scheduled for
trabeculectomy,  at University of Campinas - Brazil.  Ethics
committee approval was obtained and all participants gave
informed consent.
We excluded patients with cloudy media, previous surgery
on the superior conjunctiva, history of uveitis, infectious
retinopathy, retinal detachment, hemoglobinopathy, trauma or
previous vitreoretinal surgery.
After discussing treatment options and obtaining informed
consent, a single injection of intravitreal ranibizumab (0.5 mg)
was administered (Figure 1). Patients were seen on 1st, 3rd and
7th day after the ranibizumab injection and when it was necessary.
Success was defined as IOP ≥ 21mmHg with or without
medication. Those with persistent IOP > 21, despite maximal
tolerable medication, underwent trabeculectomy with 0.5mg/ml
mitomycin C (MMC) for one minute. Failure was defined as IOP
> 21 mmHg, phthisis bulbi, loss of light perception or additional
glaucoma surgery. The primary outcome was 6-month IOP
control.
All patients were on the open-angle glaucoma stage. Mean
IOP before the injection was 37 mmHg (7 mmHg SD). Two of
them underwent only intravitreal ranibizumab injection, having
an IOP control after the procedure with 2 anti-glaucoma
medications. Three patients were submitted to trabeculectomy
with MMC on the 7th day after the injection. At 6-month follow-
up, the mean IOP was 12mmHg (3 mmHg SD). Other outcome
Patient number 1 2 3 4 5
Age (years) 50 42 57 56 61
Diagnosis PDR PDR CRVO PDR PDR
Pre-injection IOP (mmHg) 48 32 28 40 38
Pre-injection BCVA HM 20/200 HM HM CF
Trabeculectomy Yes No Yes Yes No
6-month IOP (mmHg) 13 15 9 16 10
6-month BCVA CF CF HM HM 20/400
6-month number of
antiglaucoma medications 0 2 0 1 1
IOP – intraocular pressure; BCVA – best corrected visual acuity; CF –
count fingers at 1 meter; HM – hand movements; PDR – proliferative
diabetic retinopathy; CRVO – central retinal vein occlusion
Table 1
Clinical data of cases of intravitreal ranibizumab injection
as adjuvant treatment for neovascular glaucoma
Figure 1: (A) Right eye of a 56-year-old male with neovascular glaucoma secondary to proliferative diabetic retinopathy; (B) Three-day
follow-up of the same eye after intravitreal ranibizumab injection; note the rubeosis  iridis regression
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measures included 6-month best correct visual acuity (BCVA)
and anti-glaucoma medications to control IOP at 6-month follow
up (Table 1). All eyes showed regression of rubeosis iridis and
IOP control. Visual acuity improved in two eyes, worsened in
one eye, and remained stable in two eyes. There were no
treatment-related adverse effects.
DISCUSSION
This article describes a consecutive case series of 5 eyes
(5 patients) with NVG. Two patients underwent only intravitreal
ranibizumab injection and obtained IOP control after the
procedure under anti-glaucoma medications. Beutel et al.
evaluated the long-term effects of intraocular bevacizumab
injections as adjuvant treatment in patients with neovascular
glaucoma and hypothesized that bevacizumab may be beneficial
as adjuvant treatment because of its anti-angiogenic properties,
its ability to induce new vessels regression and to prevent
progression of angular obstruction.(2,3)
Three patients underwent trabeculectomy with mitomycin
C on the 7th day after the intravitreal ranibizumab injection,
with successful IOP control, two eyes without antiglaucoma
medication and one under one antiglaucoma medication  at 6-
month follow up (Figure 2). There are reports that intravitreal
bevacizumab injection may be an effective adjunct to
trabeculectomy in NVG.(5) Although there was no improvement
in visual acuity due to patients’ severe disease, the IOP reduction
was achieved with treatment, which traditionally does not occur
with standard filtering procedures without anti-VEGF.
Trabeculectomy for NVG eyes has been described as a
challenging treatment with a poor surgical success rate.(1)
We are unaware of previous reports using ranibizumab as
an adjuvant treatment in patients with neovascular glaucoma.
This antibody fragment inhibits all forms of biologically active
VEGF and its use is specifically intraocular, with known local
and systemic safety but we should concern about the cost of
therapy and the benefit to the patient.
These data suggest that ranibizumab may also be a useful
tool in the treatment of this devastating disease. Randomized
clinical trials are necessary to confirm the importance of this
adjuvant therapy for the treatment of NVG.
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Figure 2: Right eye of a 56-year-old male with neovascular glaucoma
secondary to proliferative diabetic retinopathy, submitted to
intravitreal Ranibizumab and trabeculectomy with 0.5% C mitomycin;
note the partially encapsulated bleb with good IOP control under one
antiglaucoma medication (6-month follow up)
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